COLORADO SPRINGS, Colo., Oct. 06, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today
announced that the Company will release third quarter 2016 financial results after the market close on Thursday, October 27, 2016.
Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) to discuss the
results. The dial-in for the conference call is (877) 561-2747 for domestic callers or (973) 409-9689 for international callers,
and the Conference ID is 89698306. There will also be a live webcast of the call on the investor relations section of the Company’s
website at www.spectranetics.com, which will be available on the Company’s website for 14 days following
the completion of the call.
Additionally, the Company announced that it will host a physician panel and Q&A session with Company management at the
Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., on November 2, 2016, following the release of the
ILLUMENATE Pivotal study. The event will begin at 10:00 a.m. Eastern Time. Space will be limited and you must RSVP to investor.relations@spnc.com to reserve a seat. There will also be a live webcast of the event on
the investor relations section of the Company’s website at www.spectranetics.com, which will be available on the Company’s website for 14 days following
the event.
About
Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures
within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial
blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above
and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated
balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets
support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire
retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets
aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for
the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen Investor.relations@spnc.com (719) 447-2292 Michaella Gallina Investor.relations@spnc.com (719) 447-2417
